Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on June 13, 2025, covering events occurring between June 13, 2025, and June 17, 2025. The filing primarily addresses executive leadership changes within the company's medical leadership team.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and employment terms.
Material Changes
- Departure of Chief Medical Officer: Dr. Fairooz Kabbinavar stepped down as Chief Medical Officer (CMO) on June 13, 2025. He will transition to providing advisory services to the company.
- Appointment of New Chief Medical Officer: Dr. Roger Sidhu was appointed as the new CMO, effective June 17, 2025, with an employment agreement dated June 16, 2025.
- Compensation Structure for New CMO:
- Annual base salary: $515,000.
- Annual performance bonus target: 45% of base salary ($231,750), subject to Board assessment.
- Equity Grant: 600,000 non-qualified stock options at an exercise price of $3.86 per share.
- Vesting Schedule: 25% vests on June 16, 2026; the remaining 75% vests in 36 equal monthly installments.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or general risk factors. Specific contingencies are outlined in the termination provisions of Dr. Sidhu's employment agreement:
- Termination for Cause/Death/Disability/Voluntary: Entitlement to unpaid base compensation, earned bonuses, and reimbursed business expenses.
- Termination Without Cause/Good Reason: Entitlement to the above plus 12 months of base salary severance and associated benefits, contingent on executing a release.
- Change of Control Provisions: If terminated without cause within 12 months prior to a pending change of control, or within 12 months after a change of control, Dr. Sidhu receives the standard severance plus immediate full vesting of all unvested stock options and equity awards.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 600,000 stock options granted to Dr. Sidhu.
- Confirm the specific performance goals set by the Board for the 45% target bonus.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed definitions of "Cause," "Good Reason," and "Change of Control."
- Assess the impact of the CMO transition on ongoing clinical trials or regulatory submissions.